In December 2023, the Biden-Harris Administration released a proposed framework for exercising government "march-in" rights on high-priced taxpayer-funded drugs. While both proponents and critics of the new rules view them as having broad scope, march-in rights can be exercised only on patents...

This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry....

Growth during the 1980s and 1990s in patenting and licensing by American universities is frequently asserted to be a direct consequence of the Bayh-Dole Act of 1980. However, there has been little empirical analysis of the effects of this legislation. This paper uses previously unexploited data...

During World War II, the U.S. government's Office of Scientific Research and Development (OSRD) undertook one of the largest public investments in applied R&D in U.S. history, entering into thousands of contracts with firms and universities to perform research essential to the war effort. Using...